Cargando…

Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis

We describe a case of severe erythrocytosis caused by testosterone replacement therapy in a 66-year-old man affected with hypogonadotropic hypogonadism (HH) determining osteoporosis, resolved by switching to restoration therapy with clomiphene citrate. The patient complained fatigue, loss of libido...

Descripción completa

Detalles Bibliográficos
Autores principales: Cangiano, B, Cacciatore, C, Persani, L, Bonomi, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510393/
https://www.ncbi.nlm.nih.gov/pubmed/28721216
http://dx.doi.org/10.1530/EDM-17-0055
_version_ 1783250177234042880
author Cangiano, B
Cacciatore, C
Persani, L
Bonomi, M
author_facet Cangiano, B
Cacciatore, C
Persani, L
Bonomi, M
author_sort Cangiano, B
collection PubMed
description We describe a case of severe erythrocytosis caused by testosterone replacement therapy in a 66-year-old man affected with hypogonadotropic hypogonadism (HH) determining osteoporosis, resolved by switching to restoration therapy with clomiphene citrate. The patient complained fatigue, loss of libido and defective erections and a spontaneous vertebral fracture despite bisphosphonate therapy and vitamin D supplementation. The examinations proved isolated HH and he was therefore treated with testosterone gel with regression of specific manifestations but elevated hemoglobin and hematocrit values. Therefore, it was decided to switch to a restoration therapy with clomiphene citrate 25 mg/die, which resulted in the resolution of symptoms without evident side effects. In a couple of months, the patient showed normalization of testosterone levels and increment of testicular volume. Since secondary hypogonadism is the consequence of an insufficient stimulation of the gonads by hypothalamic–pituitary axis, therapeutic approaches aimed to restore endogenous testosterone production should be considered in alternative to testosterone replacement, particularly if side effects intervene. Among these strategies, clomiphene citrate seems to have a high efficacy and safety profile also in the elderly with isolated HH and no evident pituitary lesion. LEARNING POINTS: Hypogonadism should always be assessed in patients with severe loss in BMD and undergo appropriate medical treatment. In hypogonadotropic hypogonadism, more approaches are available other than testosterone replacement therapy alone. In patients with severe late-onset central hypogonadism presenting with erythrocytosis even at low doses of replacement therapy, restoration therapy with clomiphene could prove to be an effective solution, particularly in patients with a reversible disruption of GNRH/gonadotropin functions. Clomiphene citrate increases gonadotropin levels and testicular volume and should therefore be considered in hypogonadal men who wish to remain fertile.
format Online
Article
Text
id pubmed-5510393
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-55103932017-07-18 Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis Cangiano, B Cacciatore, C Persani, L Bonomi, M Endocrinol Diabetes Metab Case Rep Novel Treatment We describe a case of severe erythrocytosis caused by testosterone replacement therapy in a 66-year-old man affected with hypogonadotropic hypogonadism (HH) determining osteoporosis, resolved by switching to restoration therapy with clomiphene citrate. The patient complained fatigue, loss of libido and defective erections and a spontaneous vertebral fracture despite bisphosphonate therapy and vitamin D supplementation. The examinations proved isolated HH and he was therefore treated with testosterone gel with regression of specific manifestations but elevated hemoglobin and hematocrit values. Therefore, it was decided to switch to a restoration therapy with clomiphene citrate 25 mg/die, which resulted in the resolution of symptoms without evident side effects. In a couple of months, the patient showed normalization of testosterone levels and increment of testicular volume. Since secondary hypogonadism is the consequence of an insufficient stimulation of the gonads by hypothalamic–pituitary axis, therapeutic approaches aimed to restore endogenous testosterone production should be considered in alternative to testosterone replacement, particularly if side effects intervene. Among these strategies, clomiphene citrate seems to have a high efficacy and safety profile also in the elderly with isolated HH and no evident pituitary lesion. LEARNING POINTS: Hypogonadism should always be assessed in patients with severe loss in BMD and undergo appropriate medical treatment. In hypogonadotropic hypogonadism, more approaches are available other than testosterone replacement therapy alone. In patients with severe late-onset central hypogonadism presenting with erythrocytosis even at low doses of replacement therapy, restoration therapy with clomiphene could prove to be an effective solution, particularly in patients with a reversible disruption of GNRH/gonadotropin functions. Clomiphene citrate increases gonadotropin levels and testicular volume and should therefore be considered in hypogonadal men who wish to remain fertile. Bioscientifica Ltd 2017-07-07 /pmc/articles/PMC5510393/ /pubmed/28721216 http://dx.doi.org/10.1530/EDM-17-0055 Text en © 2017 The authors http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) .
spellingShingle Novel Treatment
Cangiano, B
Cacciatore, C
Persani, L
Bonomi, M
Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis
title Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis
title_full Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis
title_fullStr Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis
title_full_unstemmed Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis
title_short Switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis
title_sort switch to restoration therapy in a testosterone treated central hypogonadism with erythrocytosis
topic Novel Treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510393/
https://www.ncbi.nlm.nih.gov/pubmed/28721216
http://dx.doi.org/10.1530/EDM-17-0055
work_keys_str_mv AT cangianob switchtorestorationtherapyinatestosteronetreatedcentralhypogonadismwitherythrocytosis
AT cacciatorec switchtorestorationtherapyinatestosteronetreatedcentralhypogonadismwitherythrocytosis
AT persanil switchtorestorationtherapyinatestosteronetreatedcentralhypogonadismwitherythrocytosis
AT bonomim switchtorestorationtherapyinatestosteronetreatedcentralhypogonadismwitherythrocytosis